AstraZeneca shares fall after efficacy findings for Covid-19 vaccine

Analysts say lower efficacy for higher dose' needs explaining, as results below those of rivals

• Coronavirus - latest updates
• See all our coronavirus coverage

AstraZeneca shares fell after the drugmaker announced efficacy results for its Covid-19 vaccine that were below those reported by rivals Pfizer/BioNTech and Moderna. The shares ended the day 3.8% lower at 80.

Results from the phase 3 trial showed the vaccine developed with the University of Oxford can protect 70.4% of people from becoming ill and, in a surprise result, up to 90% if a lower first dose is used.